Fibrobiologics, INC

FibroBiologics, Inc. received a Staff Determination from Nasdaq indicating intent to delist its securities due to failing to meet the minimum $1.00 bid price requirement for over 30 consecutive business days.

FibroBiologics, Inc. announced the appointment of Kathleen Rubins, Ph.D., a former NASA astronaut and microbiologist, to its Board of Directors, effective July 8, 2026.

FibroBiologics, Inc. announced the closing of a private placement raising $3 million, with potential for an additional $6 million upon warrant exercise, to fund working capital and general corporate purposes.

FibroBiologics, Inc. has updated its At The Market (ATM) offering, increasing the potential aggregate offering price to $7.5 million.

FibroBiologics, Inc. announced the grant of stock options to its CEO, CFO, CSO, and General Counsel, with specific vesting schedules tied to continued service.

FibroBiologics, Inc. has entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co. to sell up to $6.15 million of its common stock.

FibroBiologics reports Q2 2026 results with increased R&D spending, ongoing clinical trial delays, and a significant threat of Nasdaq delisting.

FibroBiologics reports a $5.0 million net loss for Q1 2026 while navigating going concern risks and advancing its fibroblast-based clinical pipeline.

FibroBiologics reported a significantly wider net loss in Q3 2025, driven by increased R&D expenses, while facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats.

FibroBiologics, an early-stage cell therapy company, reported significant operating losses and a substantial accumulated deficit, raising going concern doubts and receiving a Nasdaq non-compliance notice, despite advancing its preclinical and clinical programs.

FibroBiologics' Q1 2025 results reveal continued operating losses as the company progresses with its fibroblast-based therapies and prepares for clinical trials.

FibroBiologics reported its Q3 2024 financial results, highlighting ongoing research and development efforts and a net loss of $8.1 million for the nine months ended September 30, 2024.

FibroBiologics, Inc. filed an amendment to its 2025 Annual Report, providing detailed information on directors, executive compensation, security ownership, and related party transactions.

FibroBiologics, a clinical-stage biotech, reported increased net losses and a going concern doubt for 2025, while advancing its fibroblast-based therapies and addressing Nasdaq listing compliance.

FibroBiologics details its authorized capital stock, ongoing clinical programs, and potential risks in its annual report on Form 10-K.

FibroBiologics, Inc.'s 10-K filing outlines its capital structure, including common and preferred stock, and details the regulatory environment for its cell therapy product candidates.

CEO Pete O'Heeron was granted options to purchase 92,410 shares of FibroBiologics common stock.

Chief Scientific Officer Hamid Khoja was granted options to purchase 61,607 shares of FibroBiologics common stock.

FibroBiologics CFO Jason Davis was granted options to purchase 61,607 shares of common stock at an exercise price of $1.38.

General Counsel Ruben A. Garcia was granted options to purchase 61,607 shares of FibroBiologics common stock.

FibroBiologics' Chief Scientific Officer, Hamid Khoja, acquired 30,000 shares of common stock at $0.38 per share.

FibroBiologics CEO Pete O'Heeron acquired over 51,000 shares of company common stock in early March 2026, increasing his direct beneficial ownership.

FibroBiologics is holding a special meeting on September 17, 2026, to seek stockholder approval for the issuance of up to 8,163,266 shares of common stock upon warrant exercise, a move necessary to comply with Nasdaq Listing Rule 5635(d).

Fibrobiologics, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 22, 2026, to elect a director, ratify auditor appointment, approve stock issuance, and adopt a new equity plan.

FibroBiologics, Inc. submitted definitive additional materials related to its proxy statement to the U.S. Securities and Exchange Commission.

FibroBiologics, Inc. calls a Special Meeting to approve a reverse stock split to maintain Nasdaq listing and ratify recent warrant issuances totaling over 22 million shares.

FibroBiologics, Inc. will hold a Special Meeting to vote on a reverse stock split to maintain Nasdaq listing and approve the issuance of shares underlying recent warrant offerings.

FibroBiologics, Inc. has filed a definitive proxy statement with the SEC.

FibroBiologics, Inc. announces a public offering of common stock and warrants to raise capital and address ongoing Nasdaq listing compliance issues, including a recent 1-for-20 reverse stock split.

FibroBiologics, a clinical-stage biotech, filed an S-1 registration statement for the resale of up to 22.5 million common shares underlying warrants issued in recent private placements, with potential gross proceeds of $7.5 million to the company upon warrant exercise.

FibroBiologics has filed an amendment to its registration statement for the resale of up to 41,489,581 shares of common stock by YA II PN, LTD.

FibroBiologics' Chief Financial Officer, Mark Andersen, has resigned, with a transition agreement in place until November 15, 2024, while the company files an S-1 registration for a potential $25 million stock offering.

FibroBiologics has filed an S-1 registration statement for the resale of up to 16,022,644 shares of its common stock by GEM Global Yield LLC SCS, representing a significant portion of the company's public float.

FibroBiologics is seeking to raise up to $20 million through the sale of units, each comprising one share of common stock and one warrant.

Lind Global Fund III LP, along with affiliated entities and individuals, has filed a Schedule 13G, reporting beneficial ownership of 4.99% of FibroBiologics, Inc. common stock.

BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G, reporting a 2.0% beneficial ownership stake in FibroBiologics, Inc. as of June 30, 2025.

Mike Newlin has filed a Schedule 13G, disclosing beneficial ownership of 2,134,853 shares, representing 5.579% of FibroBiologics, Inc.'s common stock.

Pete O'Heeron, a key figure at FibroBiologics, Inc., has disclosed a beneficial ownership of 18.2% of the company's common stock as of January 31, 2024, through a Schedule 13G filing.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in FibroBiologics, Inc. as of December 31, 2024.

Global asset manager BlackRock, Inc. has reported a 5.1% beneficial ownership stake in FibroBiologics, Inc. as of December 31, 2024, according to a recent Schedule 13G filing.